Forum Financial Management LP Sells 17,417 Shares of Abbott Laboratories $ABT

Forum Financial Management LP cut its holdings in Abbott Laboratories (NYSE:ABT) by 27.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 46,820 shares of the healthcare product maker’s stock after selling 17,417 shares during the period. Forum Financial Management LP’s holdings in Abbott Laboratories were worth $4,807,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ABT. American National Bank of Texas boosted its position in shares of Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after buying an additional 79 shares during the last quarter. Nia Impact Advisors LLC raised its position in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares during the last quarter. Park Place Capital Corp lifted its stake in Abbott Laboratories by 11.0% during the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after acquiring an additional 81 shares during the period. Lantern Wealth Advisors LLC boosted its holdings in shares of Abbott Laboratories by 1.7% during the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock valued at $674,000 after acquiring an additional 84 shares during the last quarter. Finally, Clayton Financial Group LLC grew its stake in shares of Abbott Laboratories by 1.4% in the fourth quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock worth $779,000 after acquiring an additional 84 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ABT shares. Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. TD Cowen decreased their target price on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. JPMorgan Chase & Co. lowered their price target on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Argus dropped their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, Leerink Partners reduced their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.30.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The U.S. Justice Department reportedly closed its criminal probe into Abbott’s baby formula operations and chose not to pursue criminal charges, which removes a major overhang and reduces the risk of a damaging legal outcome. US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
• Positive Sentiment: Abbott’s Medical Devices business is being positioned for another growth phase, with new diabetes, heart rhythm, and electrophysiology products cited as potential drivers ahead of the company’s next earnings update. How Abbott’s Largest Segment Is Preparing for the Next Growth Phase
• Neutral Sentiment: Healthcare stocks were modestly higher late Monday afternoon, but Abbott still lagged peers and underperformed the sector, suggesting the stock’s move was more idiosyncratic than industry-wide. Sector Update: Healthcare Stocks Higher Late Afternoon
• Neutral Sentiment: Market commentary also highlighted Abbott’s baby formula probe being dropped by the DOJ, reinforcing the legal relief narrative, though investors may still wait for clarity on any civil penalties or follow-on costs. Update: Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks
• Negative Sentiment: Despite the DOJ news, Abbott’s shares traded lower and underperformed competitors, indicating that investors may be taking profits or focusing on broader concerns around valuation, growth, or lingering legal uncertainty. Abbott Laboratories stock underperforms Monday when compared to competitors

Abbott Laboratories Trading Down 1.4%

Abbott Laboratories stock opened at $92.78 on Tuesday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The firm has a market capitalization of $161.60 billion, a price-to-earnings ratio of 25.99, a P/E/G ratio of 1.62 and a beta of 0.63. The firm has a 50 day moving average of $89.03 and a 200 day moving average of $105.07. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.